OSE Immunotherapeutics Reports Positive Phase 2 Combi-TED Results
OSE Immunotherapeutics said the primary endpoint was met. One-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab, versus 29% with docetaxel alone; no unexpected safety signals were reported. Final data are due Oct. 25, 2026, at ESMO.
OSE Immunotherapeutics reported positive topline Phase 2 Combi-TED results: 1-year OS 47% (Tedopi+docetaxel) and 46% (Tedopi+nivolumab) vs 29% for docetaxel alone; primary endpoint met. No unexpected safety signals. Final data to be presented Oct 25, 2026 at ESMO.Material DetailsContext by AI Analy…